EGFR-mutated lung adenocarcinomas and ErbB2-positive breast and other cancers (such as gastric and lung) are critically dependent on the constitutive activity of these pathways and therapeutic targeting leads to significant clinical benefits [3–6]. The gene discussed is ERBB2; the disease is lung adenocarcinoma.